TreatSMA

Hungary will fund Spinraza treatment

Hungary has agreed to provide Spinraza treatment to all children with SMA.

Under the deal negotiated between the government of Hungary and the manufacturer, Spinraza will be provided as a standard treatment to all paediatric patients in Hungary diagnosed with spinal muscular atrophy. Treatment will be available irrespective of the so-called “SMA type”.

There have been no clinical trials or EAP in Hungary. It will be for the first time that the Hungarian medical community will have an opportunity to treat spinal muscular atrophy. We keep our fingers crossed for the success.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more